Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
|Videos|April 6, 2017
Targeting Galectin-1 With Radiation and Immune Checkpoints in Head and Neck Cancer
Author(s)Dhanya K. Nambiar, PhD
Dhanya K. Nambiar, PhD, Stanford University, discusses targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in head and neck cancer.
Advertisement
Dhanya K. Nambiar, PhD, Stanford University, discusses targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in head and neck cancer.
Galectin-1 is a carbohydrate binding protein that contributes to tumor-immune escape and disease progression. The tumors use galectin-1 as a barrier, which stops the immune response, says Nambiar.
Targeting galectin-1 and inhibiting it may allow for immune agents to infiltrate the tumor.
Advertisement
Related to this article
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Trastuzumab deruxtecan did not meet the prespecified efficacy criterion in HER2-low salivary gland carcinoma, though responses were observed in salivary duct carcinoma.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
3
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
4
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
5